This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Home
Products
Revaxis®  (diphtheria, tetanus & poliomyelitis (inactivated) vaccine (absorbed, reduced antigen(s) content))

REVAXIS®

diphtheria, tetanus & poliomyelitis (inactivated) vaccine (absorbed, reduced antigen(s) content)

Profile

REVAXIS® (Td-IPV) is indicated for active immunisation against diphtheria, tetanus and poliomyelitis in children from 6 years of age, adolescents and adults as a booster following primary vaccination. REVAXIS is not intended for primary immunisation.

Before you prescribe this vaccine please refer to the SmPC.1

Help protect your patients with REVAXIS Vaccine?

REVAXIS helps boost protection against diphtheria, tetanus and polio in a single injection.

REVAXIS is given as part of the national immunisation programme to teenagers at around 14 years of age (school year 9).

Usage

Presentation

0.5 ml prefilled syringe. Available in 1 syringe packs

Schedule

1 dose

Further dose

REVAXIS may be used as a booster following primary immunisation with inactivated or oral poliomyelitis vaccines (IPV or OPV).

REVAXIS is indicated as a booster following primary vaccination. REVAXIS is not intended for primary immunisation.

Age range6 years +
Ways to order

You can order Sanofi Vaccines in two ways: online at VAXISHOP or through our call centre. Read more about ordering vaccines.

CALL 0800 854 430

References
  1. REVAXIS® Summary of Product Characteristics.

MAT-XU-2301123 (v3.0) Date of preparation: February 2025